Ischemic Cardiomyopathy Clinical Trial
Official title:
Chinese People's Liberation Army General Hospital
It has been known that liraglutide reduces infarct size, improved left ventricular function, reduce myocardial stunning, and play a protective role in myocardial ischemia-reperfusion injury for patients with acute myocardial infarction. But it is not sure whether liraglutide can benefit patients with ischemic cardiomyopathy. This study aim to explore the effect of Liraglutide in improving cardiac function for patients with ischemic cardiomyopathy.
Investigators will enroll 400 patients with ischemic cardiomyopathy who were admitted to the
Chinese PLA General Hospital. All patients enrolled in this study will collect detailed
baseline clinical data, including blood, enzymes (troponin, creatine kinase), blood sugar,
serum creatinine, blood lipid levels (LDL lipoprotein cholesterol, high density lipoprotein
cholesterol, triglycerides, total cholesterol), brain natriuretic peptide (BNP),
inflammatory markers (high sensitivity C- reactive protein, interleukin-6), endothelin
(ET-1), pancreas glucagon-like peptide -1 (GLP-1) and superoxide dismutase (SOD).
The investigators randomly assign eligible patients in a 1:1 ratio to either liraglutide
intervention group (N = 200) or control group (N = 200), liraglutide intervention group will
accept ischemic cardiomyopathy conventional drugs and liraglutide (Novo Nordisk,
specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day), Control group will
accept ischemic cardiomyopathy conventional drugs and a placebo.
Primary end point of the study is main adverse cardiovascular events including Recurrent
myocardial infarction, recurrent angina, revascularization, all-cause death, nonfatal
myocardial infarction, nonfatal stroke, hospitalization for heart failure again. Secondary
end point of the study was 1) New York Heart Association functional class, 2) left
ventricular ejection fraction, 3) 6-minute walk test, 4) KCCQ clinical total score, 5)
changes in blood glucose levels during follow-up, blood lipid levels and body weight
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04066738 -
Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy
|
N/A | |
| Recruiting |
NCT03536052 -
Ablation at Virtual-hEart pRedicted Targets for VT
|
N/A | |
| Completed |
NCT01215253 -
Ranolazine Implantable Cardioverter-Defibrillator Trial
|
Phase 3 | |
| Completed |
NCT04508608 -
Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy
|
||
| Recruiting |
NCT05888662 -
Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)
|
N/A | |
| Completed |
NCT03857906 -
Evaluation of Prophylactic Use of a Preoperative IABP in High-Risk Coronary Artery Bypass Graft Surgery
|
||
| Completed |
NCT02501811 -
Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
|
Phase 2 | |
| Recruiting |
NCT02058771 -
Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
|
||
| Not yet recruiting |
NCT01946048 -
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy
|
Phase 1 | |
| Terminated |
NCT01759212 -
Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT01447069 -
Use of Beta-agonists in Stable Severe Congestive Heart Failure
|
N/A | |
| Recruiting |
NCT00972114 -
CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy
|
Phase 1/Phase 2 | |
| Completed |
NCT00896142 -
Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)
|
N/A | |
| Recruiting |
NCT01076660 -
Left Ventricular Structural Predictors of Sudden Cardiac Death
|
||
| Completed |
NCT00305240 -
MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
|
N/A | |
| Completed |
NCT00305214 -
MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
|
N/A | |
| Active, not recruiting |
NCT00962364 -
Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
|
||
| Recruiting |
NCT05769036 -
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
|
N/A | |
| Completed |
NCT03862339 -
The SoundScar Study The SOUNDSCAR Study
|
||
| Recruiting |
NCT03830957 -
Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker
|
N/A |